Log in
NASDAQ:JNCE

Jounce Therapeutics Stock Forecast, Price & News

$8.16
-0.06 (-0.73 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.01
Now: $8.16
$8.42
50-Day Range
$4.67
MA: $6.82
$10.95
52-Week Range
$2.79
Now: $8.16
$11.72
Volume400,282 shs
Average Volume642,873 shs
Market Capitalization$277.99 million
P/E Ratio13.16
Dividend YieldN/A
Beta2.11
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. It is also developing JTX-4014, a monoclonal antibody that is in Phase I clinical trial for combination therapy; and JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2 that is in the IND-enabling phase. The company has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Read More
Jounce Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.96 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$147.87 million
Cash Flow$1.64 per share
Book Value$5.25 per share

Profitability

Net Income$56.82 million

Miscellaneous

Employees115
Market Cap$277.99 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$8.16
-0.06 (-0.73 %)
(As of 09/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

How has Jounce Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JNCE stock has increased by 90.7% and is now trading at $8.16.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Jounce Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Jounce Therapeutics
.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Jounce Therapeutics
.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) issued its quarterly earnings data on Friday, August, 7th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.10.
View Jounce Therapeutics' earnings history
.

What price target have analysts set for JNCE?

5 analysts have issued 12-month price objectives for Jounce Therapeutics' stock. Their forecasts range from $9.00 to $28.00. On average, they anticipate Jounce Therapeutics' share price to reach $16.33 in the next twelve months. This suggests a possible upside of 100.2% from the stock's current price.
View analysts' price targets for Jounce Therapeutics
.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 1,320,000 shares, a decrease of 38.3% from the August 31st total of 2,140,000 shares. Based on an average trading volume of 1,180,000 shares, the days-to-cover ratio is presently 1.1 days. Currently, 8.0% of the shares of the company are sold short.
View Jounce Therapeutics' Short Interest
.

Who are some of Jounce Therapeutics' key competitors?

What other stocks do shareholders of Jounce Therapeutics own?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the following people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 60)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)
  • Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $8.16.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $277.99 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is www.jouncetx.com.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.